CRX.L Regulatory News (CRX)

6 Dec 2006 07:00

Cyprotex PLC06 December 2006 CYPROTEX plc NEWS 6th December 2006 (embargoed for 7am) Cyprotex announces a trading update for 2006 Cyprotex PLC (AIM: CRX), the drug discovery technology and information company,today announces a trading update for 2006. Cyprotex is pleased that 2006 has been another successful year. Full yearrevenues are expected to meet market expectations. Important opportunities within the ADME/Tox (Absorption, Distribution,Metabolism, and Excretion/Toxicity) screening market have been addressed througha further significant expansion of Cyprotex's global customer base, which nowexceeds 100 in number. This has been achieved by the offering of high valueoutsourcing services designed to address the needs of internationalpharmaceutical and drug discovery companies. Excellent retention of theCompany's customer base provides visibility for 2007, during which the groupmanagement anticipate further significant progress. Commenting on the trading update, Robert Morrisson Atwater, Chief ExecutiveOfficer of Cyprotex PLC, said: "During 2006, Cyprotex took another step towardits ambition of being recognised as the international standard setter for ADME/Tox screening. Our business plan is robust and we look forward to meeting thechallenges of the New Year." For further information:Cyprotex PLCRobert Morrisson Atwater, Chairman & Chief Executive OfficerTel: +44 (0) 1625 505 100ir@cyprotex.comwww.cyprotex.com Code SecuritiesCharles WalkerTel: +44 (0) 20 7776 1200cew@codesecurities.comwww.codesecurities.com Media Enquires:WMC CommunicationsCharlie Geller/Alex GloverTel: +44 (0) 20 7930 9030charlie.geller@wmccommunications.com Further Information Business overview Cyprotex evaluates and optimises potential drugs at an early stage in the drugdiscovery process. It provides consistent, exceptional quality analysis that canbe executed quickly, by combining two core capabilities. These capabilitiesassess the way in which the drug is processed in the body and for how long itwill work for. The Cloe Screen capability enables Cyprotex to asses theAbsorption, Distribution, Metabolism and Elimination of a potential drug. Itthen predicts a drug's pharmacokinetic value (or lifespan) using its Cloe PKcapability. The combination of these two capabilities is designed to enhance thequality of compound libraries and the number of drug candidates progressingthrough the drug pipeline - improving pharmaceutical productivity. This approachcan help inform the decision making and design process at the early stages ofdrug development, allowing problems to be identified quickly. Products Cloe(R) PK simulates how a drug will work in the body. It predicts the level andduration of a drug's efficacy in the body, so researchers can answer questionssuch as; Will my compound achieve levels in the body that will be sufficient to elicit atherapeutic effect? At a given dose, will my compound reach potentially toxic levels? How can I achieve significant improvement in compound exposure levels? Cloe Screen is a cost efficient and effective system for delivering consistent,accurate compound data. Advantages: • Highly reproducible, accurate data - validated and used byAstraZeneca, Solvay, Roche, and over 50 other Pharmaceutical and Biotechnologycompanies. • Delivery of data for core in vitro ADME and physicochemical assays iswithin 10 working days meaning it can fit in with the make-test timelines indrug discovery. • Highly cost effective due to its emphasis on high throughputengineering. • Attention to good quality customer care, with PhD-trained PrincipalScientists on hand to explain results and suggest the most appropriateexperimental strategy. Market opportunities Cyprotex's technologies offer the following benefits to partners: • It replaces traditional methods of testing relatively few compounds ata time, (often using full animal studies) with more cost-efficient evaluationmethods that screen the glut of compounds arising as a result of advances intarget discovery and chemical synthesis. • Make predictive ADME models directly from Partner's in vitro ADMEdata, so the predictive models are relevant to the particular chemistry seriesof interest • Continually improve ADME models as soon as new in vitro data isgenerated - so the models make full use of all available information and are thebest they can be • Rapidly perform "virtual ADME screening" on Partner's virtualchemistry libraries so that ADME liabilities can be designed out, savingconsiderable costs • Interpret ADME data using Cloe(R) PK software to guide medicinalchemistry and select compounds and lead series with the greatest potential This information is provided by RNS The company news service from the London Stock Exchange